**PERSONAL DATA**

Medical Officer Phone: (404) 639-3755

Clinical Trials Team Cell: (404) 579-7658

Epidemiology Branch FAX: (404) 639-6127

Division of HIV/AIDS Prevention (MS-E45) E-Mail: bchen@cdc.gov

Centers for Disease Control and Prevention (CDC)

Atlanta, GA 30333, USA

**PROFESSIONAL SKILLS AND EXPERIENCE:**

* Extensive experience developing, organizing, and sustaining large, global, multilateral, cooperative, productive research and programmatic unit in emergently critical domain in public health (HIV prevention trials and immunization safety).
* Knowledge of current HIV/AIDS prevention/control programs, especially HIV vaccines, U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and prevention of medical transmission of HIV via injections or blood transfusion.
* Extensive knowledge of pre- and post-licensure processes for pharmaceutical products, especially vaccines and devices, especially research and development, regulatory/licensure, recommendation/ policy development and procurement process.
* Extensive knowledge of vaccine safety and injection safety, including pharmacoepidemiology, risk/safety assessment, risk communication, risk minimization, and risk management of existing and new products.
* Extensive theoretical and practical knowledge of multiple vaccine preventable diseases in developing and developed countries; first author of “Epidemiologic Methods for Immunization Programs” in Epidemiologic Reviews 1996;18:99-117.
* Extensive experience in training public health professionals, including first EIS Officers from the former Soviet Union, Japan, Korea, Belgium, and Poland.
* Fluent language skills in verbal and written English, French, Chinese in international public health and program contexts.
* Other notable personal skills in creativity, ethics, intellectual curiosity and rigor, and leadership.

**PROFESSIONAL POSITIONS AND RESPONSIBILITIES:**

Jan 2012+ Medical Officer, Clinical Trials Team, Division of HIV/AIDS Prevention

* Coordinate and lead preparations of CDC application to join NIH HIV/AIDS Clinical Trial Network as a Clinical Trial Unit (CTU) with associated Clinical Research Sites (CRS) in Botswana, Kenya, Thailand, and Uganda.
* Serve as lead CDC technical expert on HIV vaccines.
* Support Kisumu, Kenya site in HIV prevention studies.
* Associate Editor, Vaccine.

June 2008-Dec 2011 HIV Vaccine & Special Studies Team Leader; Division of HIV/AIDS Prevention

* Supported Kisumu, Kenya site in HIV prevention studies, notably participation in HPTN 052, a Phase III, two-arm, multi-site, randomized trial demonstrating 96% effectiveness in preventing the sexual transmission of HIV in HIV-serodiscordant couples via earlier anti-retroviral therapy; deemed “Breakthrough of the Year” for 2011 by Science magazine.
* In addition to HIV Vaccine-related duties, added responsibilities to develop, implement, and evaluate male circumcision interventions to prevent HIV transmission in the U.S.
* Serve as CDC technical expert on unsafe injection practices, blood safety, and other issues resulting in HIV transmission.

Dec 2006-2008 HIV Vaccine Team Leader; Division of HIV/AIDS Prevention

* Directs the development, implementation and evaluation of biomedical, epidemiologic and social behavioral research studies related primarily to HIV vaccine clinical trials.
* Serve as the CDC technical expert supporting national and international workgroups/committees focused on advancing HIV vaccine clinical efficacy research initiatives, and the continuing development of national and global HIV vaccine guidelines and policies.
* Oversees all phases of scientific studies conducted by the HIV Vaccine Team of the Epidemiology Branch.
* Responsible for CDC’s engagement with the U.S. Partnership for AIDS Vaccine Evaluation (PAVE).

2004-2006 Injection Safety Coordinator, Medical Transmissions Team Leader (July-Dec 2005) Global AIDS Program (GAP), CDC, Atlanta, GA

* Serve as expert technical advisor on preventing medical transmission of HIV to GAP, other relevant CDC divisions, Ministries of Health, U.S. Agency for International Development (USAID), WHO, UNAIDS, and other public health partners.
* Monitor and manage cooperative agreements and contracts for technical assistance, training, with annual budget of ~$15 million for injection safety and ~$45 million for blood safety funded by PEPFAR. Major strategy shifts implemented include, identifying optimal budget allocations for the project, adding phlebotomy and other high risk procedures, enhancing role of monitoring and evaluation, refining role of retractable syringes.
* Develop operational research on provision of safe blood and safe injection healthcare services, including appropriate budgeting for management of medical wastes, enhancing rational injections via standard treatment guidelines, role of informal sector in medical transmission, and overcoming barriers to effective sharps injury surveillance in developing country health care workers..

2002-2004 Chief, Immunization Safety Branch, National Immunization Program, CDC, Atlanta, GA

1994-2002 Chief, Vaccine Safety and Development Activity, National Immunization Program, CDC

1992-1994 Chief, Vaccine Safety Activity, Division of Immunization, CDC.

* Help maintain public confidence in immunizations in the U.S. by:
  + Rebuilding and modernizing the US vaccine safety monitoring system at a time when vaccine-preventable diseases are at all time lows and public attention is shifting to the potential risks of immunization.
  + Successfully advocating for the greater independence and separation of vaccine risk assessment functions from vaccine risk management and vaccine promotion functions of the National Immunization Program (NIP).
  + Monitor the human vaccines in routine use to detect new safety concerns and assess the magnitude of their risks (if any), their pathophysiology, and risk factors.
  + Supervise ~25 staff members, 10 trainees/fellows and annual budget of $16 million arrayed in four teams: Safety Signals, Safety Studies, Vaccine Acceptance and Risk Perception, and Vaccine Development.
* Created the Vaccine Adverse Event Reporting System (VAERS), NIP’s largest (N~16,000/year) and most complex surveillance system to detect signals of potential vaccine safety concerns.
* Created the Vaccine Safety Datalink (VSD) project, CDC’s largest collaborative project with managed care. Computerized vaccination and medical records are linked on cohort of >6 million persons to provide scientifically rigorous answers to vaccine safety questions.
* Created the Clinical Immunization Safety Assessment (CISA) centers, a network of tertiary centers for standardized intensive clinical study of persons with vaccine adverse events and potential contraindications (e.g., genetic and other risk factors).
* Created the Brighton Collaboration, an international voluntary consortium to develop standardized case definitions for adverse events following immunizations (e.g., fever). Development of a “common language” among researchers is key to advancing the science of vaccine safety.
* Conducted many key studies on vaccine safety, thereby provide scientific rigorous data on the (rare) risks of immunizations for policy making at both the population and individual levels.
* Created the Institute of Medicine (IOM) Immunization Safety Review Committee to provide a rapid assessment of new vaccine safety hypotheses for their biologic plausibility and public health importance.
* Launched the Vaccine Risk Communications and Research (VARICORE) initiative to help correct misinformation from anti-vaccine groups about the safety and importance of vaccines.

4-7/1999 Medical Officer, Vaccines and Biologicals Cluster, World Health Organization, Geneva, Switzerland (on detail from CDC).

* Planned and launched the Safe Injection Global Network (SIGN), to help develop solutions to probably the largest iatrogenic disaster of the 20th century: transmission of blood-borne pathogens from the introduction of syringes and needles.
  1. Medical Epidemiologist, Division of Immunization, CDC, Atlanta, GA
* Project officer for the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) project.
* Conducted pivotal study on whether Russian diphtheria vaccine was efficacious or not, guiding the strategies to control resurgence of diphtheria in the former Soviet Union during the 1990's.
* Conducted pivotal studies on measles that defined 1) the laboratory correlate of protection against measles now used as the “gold standard”, 2) the potential for explosive spread of measles via aerosolization, and 3) the risk for “post-honeymoon period” outbreaks .

1987-88 Chief, Health Resources and Services Branch, AIDS Office, City and County of San Francisco Department of Public Health, California

* Managed and preserved the innovative “out-of-hospital” continuum of services for persons with AIDS in San Francisco at a critical time during the AIDS epidemic.
* Conducted the first HIV/AIDS assessment of People’s Republic of China for WHO’s Global Programme on AIDS.

**EDUCATION AND TRAINING**

* 1. Doctor of Medicine (**M.D.**) Pritzker School of Medicine

University of Chicago, Chicago, Illinois

l979-80 Master of Arts (**M.A.**), Committee on Public Policy Studies

University of Chicago, Chicago, Illinois

* 1. Bachelor of Science (**B.S.** Honors Biology, Chemistry)

College of Liberal Arts & Sciences

University of Illinois, Urbana, Illinois

**Post\_Graduate Training:**

1. Fellow, International Society of Pharmacoepidemiology (**F.I.S.P.E.**)

1989 New England Epidemiology Institute Summer Program

1986-87 Preventive Medicine Residency

Division of Field Services, Epidemiology Program Office

Centers for Disease Control, Atlanta, Georgia

Assigned to:

Epidemiological Studies & Surveillance Section

Office of Environmental Health Hazard Assessment

California Department of Health Services

1984-86 Epidemic Intelligence Service (EIS) Officer

Surveillance, Investigations and Research Branch

Division of Immunization, Center for Prevention Services

Centers for Disease Control, Atlanta, Georgia

1982-84 Internal Medicine - Primary Care

Michael Reese Hospital, Chicago, Illinois

**HONORS AND AWARDS**

2011 **NCHHSTP Director’s Recognition Award:** for its actions in overcoming difficult circumstances preparing the Kisumu Field Station for participation in the pivotal HPTN 052 Trial, thereby providing the first clear evidence that treating HIV infected persons early can dramatically reduce sexual transmission of HIV.

2010 **Public Health Service Unit Commendation:** for its exceptional leadership, teamwork and dedication in obtaining lab accreditation and launching a clinical trial between June, 2008 and December, 2009.

2009 **CDC Charles C. Shepard Science Award/Laboratory and Methods Nomination:** for study of Anti-Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine-Associated Guillain-Barré Syndrome.

2007 **Public Health Service Outstanding Unit Citation:** for “extraordinary vision, professional leadership, teamwork, and dedication in responding to The President’s Emergency Plan for AIDS Relief.”

2005 **National Center for HIV and STD Prevention Honor Award:** for its vision, endurance, and compassion in preventing/treating HIV, while expanding its operations to help implement the President’s Emergency Plan for AIDS Relief.

2004 **Public Health Service Outstanding Unit Citation:** for enhancing the Nation’s capacity for smallpox preparedness and emergency response through planning and implementing the National Smallpox Vaccination Program.

2004 **Public Health Service Unit Commendation:** for the development and oversight of the Vaccine Safety Datalink (VSD) project Data Sharing program to meet the urgent but conflicting needs for increased transparency of CDC research to enhance public credibility and the VSD project.

2004 **CDC Charles C. Shepard Science Award/Laboratory and Methods Nomination:** for a retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.

2003 **CDC/NIP Stephen R. Preblud Excellence in Science Award:** for model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa.

2003 **CDC Charles C. Shepard Science Award/Laboratory and Methods Nomination:** for model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa.

2002 **Public Health Service Unit Commendation:** for exemplary performance of duty in the investigation of a smallpox vaccine reaction among CDC smallpox responders.

2002 **CDC/ATSDR Group Honor Award:** for extraordinary contributions and commitment to developing the course curriculum, training materials, and exercises, and for providing exceptional logistical management for the Smallpox Response Response Team Training.

2001 **CDC/ATSDR Lifetime Scientific Achievement Award Nomination:** for many studies of vaccine safety yielding essential information for public health policy makers.

2000 **Public Health Service Outstanding Unit Commendation/DHHS Secretary's Award for Distinguished Service**: for work on the Rotavirus Vaccine and Intussusception investigation.

1998 **Bicentennial Unit Commendation**: for extended active duty service during PHS Bicentennial year.

1998 **Public Health Service Outstanding Unit Commendation:** for work performed as a member of the vaccine-preventable disease surveillance training team.

1998 **Kaiser Permanente Medical Care Program, Division of Research, Best Published Paper July 1997-June 1998**: Risk of chronic arthropathy among women after rubella vaccination.

1997 **Public Health Service Outstanding Unit Commendation:** for role in attaining the 1996 Childhood Immunization Initiative and the highest immunization levels ever in the U.S..

1997 **Public Health Service Unit Commendation:** for revising and updating the Adverse Events and Contraindications sections of the Recommendations of the Advisory Committee on Immunization Practices (ACIP).

1997 **Public Health Service Unit Commendation:** for exceptional role in maintaining public confidence in immunizations.

1996 **Regular Corps Ribbon:** for assimilation into the Regular Corps of Commissioned Corps.

1996 **Public Health Service Unit Commendation:** for valuable contribution to developing an integration of the Vaccine Adverse Event Reporting System and the Vaccine Injury Compensation Program database.

1996 **Public Health Service Citation**: for support & contribution to the vaccine-safety efforts of the Advisory Commission of Childhood Vaccines.

1996  **Public Health Service Outstanding Service Medal:** for outstanding leadership in developing a vision and guiding scientific and policy efforts to improve vaccine safety, thereby promoting public confidence in the nation=s immunization program.

1995  **Public Health Service Foreign Duty Award:** for extended service overseas in Burundi for investigation of a measles outbreak.

1993  **Public Health Service Unit Commendation:** for valuable contribution to the development of the Combatting Childhood Communicable Diseases end-of-project documents on the lessons learned and the achievements from a decade of child survival activities in Africa.

1992  **Public Health Service Unit Commendation:** for an outstanding team effort in the investigation of a possible association between Guillain-Barré syndrome and the 1990-91 influenza vaccine.

1991 **Public Health Service Achievement Medal:** for sustained high-quality scientific work on the epidemiology of vaccine-preventable diseases, especially his noteworthy contributions to the study of measles, diphtheria, pertussis, and poliomyelitis.

1990 **Public Health Service Commendation Medal:** for contributions to study of vaccine safety and the development of a reporting system for adverse events following vaccination.

l982  **Upjohn Award for Outstanding Achievement:** during four years of medical school, Pritzker School of Medicine, University of Chicago

**MEDICAL LICENSURE AND BOARD CERTIFICATION**

6/1979 National Board of Medical Examiners Part I

5/1981 National Board of Medical Examiners Part II

3/1983 National Board of Medical Examiners Part III

1982-1987 Illinois #036-067354

1987- present California #G59509

1990- present American Board of Preventive Medicine #50404

2004- present Fellow, International Society of Pharmacoepidemiology (FISPE)

**PROFESSIONAL MEMBERSHIP**

1. American Public Health Association
2. American College of Preventive Medicine
3. Epidemic Intelligence Service (EIS) Alumni Association
4. International Society for Pharmacoepidemiology

**PROFESSIONAL EXPERIENCE**

**Professional Committees:**

2007+ WHO-UNAIDS HIV Vaccine Advisory Committee

2008-10 European Malaria Vaccine Development Association Challenge Trials Working Group

Vaccine Vigilance Technical Working Group, Health Canada

CDC representative on the Partnership for AIDS Vaccine Evaluation (PAVE) Executive Steering Group

1999-05 Steering Committee, Brighton Collaboration

1999-04 WHO Steering Committee on Immunization Safety

1999-04 WHO Global Vaccine Safety Advisory Committee

1996-99 Board of Directors, International Society for Pharmacoepidemiology (ISPE)

1995-04 CDC Liaison, Subcommittee on Vaccine Safety, National Vaccine Advisory Committee

1995-98 Institute of Medicine, Vaccine Safety Forum

1994-96 Secretary-Treasurer, EIS Alumni Association

1994-95 Committee on Standards for Pharmacoepidemiology Studies Used for Regulatory Purposes, ISPE

1991-93 Governing Council, Epidemiology Section, American Public Health Association.

1989-91 Section Council, Epidemiology Section, American Public Health Association.

1987-89 Asian-American AIDS Task Force, San Francisco

**Health Policy/Program Management:**

10/03 Consultant, WHO, Immunization Safety, China

1998-00 Consultant, Agence Produit de Santé, France

11/99 Consultant, WHO, Immunization Safety, China

1/98 Consultant, WHO, Immunization Safety, Bishkek, Kyrgystan.

2/97 Chairman, World Health Organization (WHO) Steering Group on the Development of Jet Injectors for Immunizations.

10/95 Consultant, WHO, Review the Safety of Jet Injectors, London.

3/94 Consultant, UNICEF, Evaluate the Tanzanian Expanded Program on Immunizations (EPI) for ability to conduct surveillance for adverse events following immunization (AEFI).

7/93 Rapporteur, WHO/European Regional Office, Diphtheria in Europe Meeting, St. Petersburg.

11/92 Consultant, U.S. Agency for International Development (USAID), Assess the diphtheria outbreak and vaccine supply in Ukraine.

1989-99 Public Health Service Task Force for Safer Childhood Vaccines

9/91 Consultant, WHO/Pan American Health Organization (PAHO), Develop options for Vaccine Adverse Events Surveillance.

11/90 Consultant, WHO/EURO, WHO Working Group on Immunization of Tourists and Other Travellers, Venice, Italy.

1988-90 Consultant, WHO/Global Program on AIDS, Development of Short and Medium\_Term AIDS Surveillance and Prevention Plan, People's Republic of China.

1987-88 Plan, develop, and coordinate, the out\_of\_hospital continuum of services for persons with AIDS; health services research; proposal writing; contract management.

11/85 Consultant, UNICEF, Review and develop plan for acceleration of EPI and other related child survival activities, Madagascar.

**Journal Reviewer:**

American Journal of Epidemiology American Journal of Public Health

**Archives of Disease in Childhood** Bulletin of World Health Organization

Archives of Internal Medicine Clinical Infectious Disease

Drug Safety Emerging Infectious Diseases

Epidemiology and Infection Expert Opinion on Drug Safety

Human Vaccines International Journal of Epidemiology

Journal of American Medical Association Journal of Infectious Diseases

Journal of the Neurological Sciences Journal of Pediatrics

Journal of Public Health Policy Lancet

New England Journal of Medicine Pediatrics

Pediatric Infectious Disease Journal Pharmacoepidemiology and Drug Safety

PLoS One Public Health Reports

Regulatory Toxicology and Pharmacology Vaccine

**Study Reviewer**

Vaccine Adverse Events in Kenya (VAEIK) Study: 2010+

The Ethiopian PCV-10 Study: 2012+

**Journal Editorial Board:**

Vaccine: Associate Editor, Jan 2010+

Human Vaccines: Editorial Board, Jan 2005+

**Scientific Conferences:**

2012 Intl Conf on Pharmacoepidemiology, Barcelona: Core Committee

2011 Intl Conf on Pharmacoepidemiology, Chicago: Core Committee

2010 AIDS Vaccine Conference, Atlanta: Local Organizing Committee

**Outbreak Investigations:**

2001 Suspected “cellulitis” among CDC smallpox vaccinees

1999 Rhesus rotavirus tetravalent vaccine and intussusception

1990+ Whether influenza vaccination causes Guillain-Barré Syndrome (GBS).

11/92 Evaluate cause and vaccine needs, diphtheria in Ukraine.

4/92 Evaluate sudden infant deaths after diphtheria-tetanus-pertussis (DTP) vaccination, Taiwan.

1989 Evaluate impact of EPI on acute and long term measles morbidity and mortality; role of schools and health centers in transmission, Burundi.

4/87 Evaluate community impact of pentachlorophenol/dioxin exposure, Oroville, California

1986 Conduct surveillance and control outbreak of poliomyelitis, evaluate vaccine efficacy of a new more potent injectable polio vaccine, Senegal .

8/85 Study of transmission patterns of pertussis, Laughlin Air Force Base, Del Rio, Texas

5/85 Study of contact and airborne transmission; epidemic modeling; case\_control study for risk factors for measles, Elgin, Illinois.

3/85 Study of vaccine adverse events and protective antibody titers by new laboratory assays., measles, Boston metropolitan area, Massachusetts

10/84 Study of adult to adult transmission of pertussis in the workplace, Seattle, Washington

**Surveillance:**

1988-04 Adverse events following immunizations, United States

1990-91 Seroprevalence of polio immunity in inner-city population, United States

1984-86 Diphtheria, Pertussis, United States

1971-81 Diphtheria, United States

**Teaching:**

2008+ Adjunct Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

1997+ Adjunct Associate Professor, Department of International Health, Rollins School of Public Health, Emory University, Atlanta, GA

1994+ Instructor, Epidemiology in Action course. Rollins School of Public Health, Emory University, Atlanta, GA

6/92 Vaccine Preventable Disease Surveillance Course, Nouakchott, Mauritania.

3/91 "Issues in Vaccine Pharmacoepidemiology". Pharmacoepidemiology Workshop, Univ. of North Carolina School of Public Health.

1991 Developed epidemiologic teaching exercise: "A measles outbreak in a highly immunized population: health sector Muyinga, Burundi 1988-1989".

1988+ Instructor, Epidemiology, Prevention and Control of Vaccine-Preventable Diseases

7/86 Instructor, EIS Course, Atlanta, GA

**EIS Officers Supervised:**

2011-13 Rennatus Mdobo PhD

2009-11 Charbel El Bcheraou, MSc, PhD

2007-09 Christina Dorell MD MPH; (Wan-Ting Huang MD)

2005-07 (Fatma Soud PhD)

2004-06 Miriam Sabin PhD

2003-05 Angela Calugar MD MPH

2002-04 Alena Y Khromova MD MPH

2001-03 Weigong Zhou MD PhD

1999-01 Thomas M Verstraeten MD MSc

1997-98 Hiroshi Takahashi MD MSc

1997-99 Piotr Kramarz MD PhD

1996-98 Vitali Pool MD

1995-97 Jenifer C. Lloyd DVM MSPH

1994-96 Steven R Rosenthal MD MPH

**Emory MPH Students Supervised:**

2010-12: Baevin Carbery

2008-09: Christina Maria Via; Renee Yu

2007-08: Amy Elizabeth Berrera

2005-06: Fauzia Khan, Jennifer Lasley

2002-03: Brenda Thompson, Kattrina Hancy

Lisa Lindsay

Dan Salmon

**PUBLICATIONS**

Journal Articles:

1. Ambrose HW, Givens RP, Chen R, Ambrose KP. Distastefulness as a defense mechanism in Aplysia braziliana. Marine Behavior and Physiology. 1971; 6:57\_64.
2. Berkelhamer JE, Noyes EJ, Chen RT. Child health policy \_ an overview of federal involvement, Advances in Pediatrics, 29:211\_28, l982.
3. Chen RT, Broome CV, Weinstein RA, Weaver R, Tsai TF. Diphtheria in the United States, l971\_l981, Am J Public Health 1985; 75:1393\_97.
4. Chen RT, Spira TJ. Tetanus prophylaxis in AIDS patients (letter). JAMA; l986, 255:l061.
5. Chen RT, Rutherford GW, Payne SF, Barnhart JL, Baskett LH. Use of hospitals by patients with AIDS in San Francisco (letter). N Engl J Med 1988; 319:1671\_1672.
6. Chen RT, Goldbaum GM, Wassilak SGF, Markowitz LE, Orenstein WA. An explosive point\_source measles outbreak in a highly immunized population: modes of transmission and risk factors for disease. Am J Epidemiol 1989;129:173\_182.
7. Orenstein WA, Bernier RH, Chen RT. Pertussis \_ a disease and a vaccine that are not going away. West J Med 1989;150:339\_341.
8. Lemp GF, Payne SF, Rutherford GW, Hessol NA, Winkelstein W, Wiley JA, Moss AR, Chaisson RE, Chen RT, Feigal DW, Thomas PA, Werdegar D. Projections of AIDS morbidity and mortality in San Francisco. JAMA 1990;263:1497\_1501.
9. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-1042.
10. Chen RT, Moses JM, Markowitz LE, Orenstein WA. Adverse events following measles-mumps-rubella and measles vaccination in college students. Vaccine 1991, 9:297-299.
11. Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA. Principles of measles control. Bull WHO 1991;69:1-7.
12. Woodruff BA, Chen RT. Oral typhoid vaccination for travelers (letter). Arch Intern Med 1991; 151:619-620.
13. Fine PEM, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992;136:121-35.
14. Chen RT, Orenstein WA. Recent developments in vaccines for travellers: viral diseases. In: Lobel HO, Steffen R, Kozarsky PE, eds. Proceedings of the Second Conference on International Travel Medicine, May 1991, Atlanta, GA. Atlanta: International Society of Travel Medicine, 1992:119-21.
15. Chen RT. The Vaccine Adverse Event Reporting System (VAERS): a new resource for data on vaccine safety for travelers. In: Lobel HO, Steffen R, Kozarsky PE, eds. Proceedings of the Second Conference on International Travel Medicine, May 1991, Atlanta, GA. Atlanta: International Society of Travel Medicine, 1992:128-30.
16. Farizo KM, Strebel PM, Chen RT, Kimbler A, Cleary TJ, Cochi SL. Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis 1993;16:59-68.
17. Longini IM, Halloran ME, Haber M, Chen RT. Measuring vaccine efficacy from epidemics of acute infectious agents. Statistics in Medicine 1993;12:249-63.
18. Simon PA, Chen RT, Elliott JA, Schwartz B. Outbreak of pyogenic abscesses after diphtheria and tetanus toxoids and pertussis vaccination. Pediatr Infect Dis J 1993;12:368-71.
19. Chen RT, Weierbach R, Bisoffi Z, Cutts F, Rhodes P, Ramaroson S, Ntembagara C, Bizimana F. A "post-honeymoon period" measles outbreak in Muyinga Sector, Burundi. Int J Epidemiol 1994;23:185-93.
20. Chen RT, Rastogi SC, Mullen JR, Hayes S, Cochi SL, Donlon JA, Wassilak SG. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-50.
21. Chen RT, Haber P, Mullen JR. Surveillance of the safety of simultaneous administration of vaccines, the CDC experience. Ann NY Acad Sci. 1995;754:309-20.
22. Wassilak SGF, Glasser JW, Chen RT, Hadler SC, and Vaccine Safety Datalink Investigators. Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects. Ann NY Acad Sci. 1995;754:377-82.
23. Rosenthal S, Chen RT. Reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85:1706-9.
24. Barnett ED, Chen R. Children and international travel: immunizations. Ped Infect Dis J. 1995;14:982-92.
25. Chen RT. Active surveillance for vaccine adverse effects (letter). Lancet 1995;345:1369.
26. Grabowsky M, Hadler SC, Chen RT, Edwards KM. Vaccination in the immunocompromised person. Bull Rheum Dis 1995;44:3\_6.
27. Rosenthal S, Chen R, Hadler SC. The safety of acellular pertussis vaccine versus whole cell pertussis vaccine: a post-marketing assessment. Arch Pediatr Adolesc Med. 1996;150:457-60.
28. Chen RT, Rosenthal S. An errant critique that misses the mark. Arch Pediatr Adolesc Med. 1996;150:464-5. Editorial.
29. Chen RT, Hausinger S, Dajani AS, Hanfling M, et al. Seroprevalence of Antibody Against Poliovirus in Inner-City Preschool Children: Implications for Vaccination Policy in the United States. J Am Med Assoc 1996;276:1639-45.
30. Chen RT. Oral poliomyelitis vaccines. Lancet 1996;347:1496. Letter.
31. ISPE ad hoc working group. Guidelines for good epidemiology practices for drug, device, and vaccine research in the United States. Pharmacoepidemiology and drug safety. 1996;5:333-8.
32. Chen RT, Orenstein WA. Epidemiologic Methods for Immunization Programs. Epidemiol Rev. 1996;18:99-117.
33. Davis R, Vadheim C, Black S, Shinefield H, Chen R, et al. Immunization tracking systems: experience of the CDC Vaccine Safety Datalink Sites. HMO Practice 1997;11:13-17
34. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Reports 1997;112:10-20.
35. Ellenberg SS, Chen RT. Riesgos de la vacunacion. Medico Interamericano 1997;16:220-4.
36. Chen RT, Glasser J, Rhodes P, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC. The Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United States. Pediatrics 1997;99:765-73.
37. Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-3.
38. Pool V, Chen R, Rhodes P. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura (Letter). Pediatr Infect Dis J. 1997;16:423-4.
39. Heijbel H, Chen RT, Dahlquist G. Cumulative incidence of childhood-onset IDDM is unaffected by pertussis immunization. Diabetes Care 1997;20:173-5.
40. Chen RT. Safety of acellular pertussis vaccine: follow-up studies. Dev Biol Stand 1997;89:373-5.
41. Davis RL, Marcuse E, Black S, Lewis E, Chen R, et al. MMR2 at 4-5 years and 10-11 years of age. A comparison of adverse event rates in the Vaccine Safety Datalink (VSD) Project. Pediatrics 1997;100:767-771.
42. Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, Hadler S, Chen R, et al. Risk of chronic arthropathy following rubella vaccination. JAMA 1997; 278:551-6.
43. Tuttle J, Chen RT, et al. GBS after tetanus-toxoid containing vaccines in adults and children: what is the risk? Am J Public Health. 1997;87:2045-8.
44. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, Chen RT. Impact of the anti-vaccine movements on pertussis control: the untold story. Lancet 1998;351:356-61.
45. Chen RT, DeStefano F. Vaccine adverse event: causal or coincidental? (Commentary). Lancet 1998;351:611-2.
46. Bisgard KM, Hardy IRB, Popovic T, Strebel PM, Wharton M, Chen RT, Hadler SC. Respiratory diphtheria in the United States, 1980-1995. Am J Public Health 1998;88:787-91.
47. Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, Shinefield H, Chen RT, Ellenberg SS, and the VAERS and VSD working groups. Comparative safety of two recombinant hepatitis b vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998;51:503-10.
48. Parashar UD, Holman RC, Bresee JS, Clarke MJ, Rhodes PH, Davis RL, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Marcy M, Vadheim CM, Ward JI, Chen RT, Glass RI, and the Vaccine Safety Datalink Team. Epidemiology of Diarrheal Disease among Children Enrolled in Four West Coast Health Maintenance Organizations. Pediatr Infect Dis J 1998;17:605-11
49. Chen RT, Hibbs B. Vaccine safety: current and future challenges. Ped Annals 1998;27:445-64.
50. Weniger BG, Chen RT, Jacobson SH, Sewell EC, Deuson R, Livengood JR, Orenstein WA. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine 1998;16(19):1885-1897.
51. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT. Association of the Guillain-Barre syndrome with the 1992-93 and 1993-94 influenza vaccines. N Engl J Med 1998;339:1797-1802.
52. Mullooly J, Drew L, DeStefano F, Chen R, O=koro K, Swint E, Immanuel V, Ray P, Lewis N, Vadheim C, Lugg M, and the Vaccine Safety Datalink Team. Quality of HMO vaccination databases used to monitor childhood vaccine safety. Am J Epidemiol 1999;149:186\_94
53. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, Lezhava T, Williams WW. Safety of Revaccination with Pneumococcal Polysaccharide Vaccine. J Am Med Assoc 1999;281:243\_248.
54. Garguillo PM, Kramarz P, DeStefano F, Chen RT. Principles of epidemiologic research on drug effects (letter). Lancet 1999;353:501.
55. DeStefano F, Chen RT. Negative association between MMR and autism (commentary). Lancet 1999,353:1987.
56. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. J Am Med Assoc 1999;282:47-53.
57. Singleton JA, Lloyd JC, Terracciano GJ, Salive ME, Chen RT and VAERS Group. An overview of the Vaccine Adverse Event Reporting System as a surveillance system. Vaccine 1999;17:2908-2917.
58. Davis RL, Shinefield H, Rubanowice D,Lewis N, Gu D, Black SB, Destefano F, Gargiullo P, Mullooly JP, Thompson RS, Chen RT and the CDC Vaccine Safety Datalink Group. Immunization levels among premature and low birth weight children, and risk factors for delayed up-to-date status. JAMA. 1999;282:547\_553 .
59. Hutin YJF, Chen RT. Injection safety: a global issue. Bull WHO 1999; 77: 787-8.
60. Chen RT. Vaccine risks: real, perceived, and unknown. Vaccine 1999; 17: S41-6.
61. Chen RT, Hardy IRB, Rhodes PH, Tishchenko DK, Moiseeva AV, Marievsky VF. Ukraine 1992: Vaccine Effectiveness and Other Preludes to Understanding the Recent Resurgence of Diphtheria in the Former Soviet Union. J Infect Dis 2000;181(Suppl 1):S178\_S183
62. Kramarz P, DeStefano F, Gargiullo PM, Lieu TA, Davis RL, Chen RT, Mullooly JP, Black SB, Bohlke K, Ward JI, Okoro CA, and the Vaccine Safety Datalink Team. Influenza vaccination in children with asthma in Health Maintenance Organizations. Vaccine 2000; 18: 2288-94.
63. Chen RT, DeStefano F,. Davis RL, Jackson LA, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Ward JI, Marcy SM, & the Vaccine Safety Datalink Team. e Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA Bull WHO 2000;78:186-194.
64. Salmon, DA., Gangarosa EJ, Chen RT. Health Consequences of Exemptions From Immunization Laws (letter). JAMA 2000; 283: 1141-2.
65. Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese Encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. Vaccine 2000; 18: 2963-2969.
66. Kramarz P, DeStefano F, Gargiullo PM, Lieu TA, Davis RL, Chen RT, Mullooly JP, Black SB, Shinefield HR, Bohlke K, Ward JI, Marcy MS, and the Vaccine Safety Datalink Team.. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Arch Fam Med 2000;9:617-623.
67. Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: an epidemiological review. Paediatrics Drugs 2000;2:273-90.
68. Belay ED,Holman RC, Clarke MJ, DeStefano F, Shahriari A, Davis RL, Rhodes PH, Thompson RS, Black SB, Shinefield HR, Marcy SM, Ward JI, Mullooly JP, Chen RT, Schonberger LB. The Incidence of Kawasaki Syndrome in West Coast Health Maintenance Organizations. Ped Infect Dis J; 2000;19:828-32.
69. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS, and the VAERS Working Group. Infant Immunization With Acellular Pertussis Vaccines in the United States:Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000;106(4). URL: http://www.pediatrics.org/cgi/content/full/106/4/e51;
70. Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman, RE. Excess individual and community risks associated with personal exemptions to immunization: An evaluation of measles and pertussis in Colorado, 1987-1998. JAMA 2000;284:3145-50.
71. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, MulloolyJ, Drew L, Black S, Shinefield H, Lewis E, Ward J, Marcy SM, Eriksen E, Destefano F, Chen RT for the Vaccine Safety Datalink Team. A Case-Control Study of MMR and Other Measles-Containing Vaccines and Risk for Inflammatory Bowel Disease. Results from the Vaccine Safety Datalink Study. Arch Pediatr Adolesc Med. 2001 Mar;155(3):354\_359. .
72. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmunity 2001;16:309-18
73. Rota JS, Salmon DA, Rodewald LE, Chen RT, Hibbs BF, Gangarosa EJ. Non-medical exemptions to state immunization laws: formal processes are associated with fewer exemptions. Am J Pub Health 2001;91:645-8.
74. Kramarz P, DeStefano F, Gargiullo PM, Chen RT, Lieu TA, Davis RL,, Mullooly JP, Black SB, Shinefield HR, Bohlke K, Ward JI, Marcy MS. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr. 2001 Mar;138(3):306\_10.
75. Kramarz P, France EK, Black SB, Shinefield H, Ward JI, Chang E, Destefano F, Chen RT, et al. Population Based Study of Rotavirus Vaccination and Intussusception. Ped Infect Dis J 2001; 20:410-6.
76. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991-1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001;107(5). URL: http://www.pediatrics.org/cgi/ content/full/107/5/e83.
77. Destefano F, Davis RL, Chen RT. Autism and MMR Vaccination: Controversy Laid to Rest? CNS Drugs 2001;15:831-7.
78. Chen RT, Pool V, Takahashi H, Weniger B, Patel B. Combination vaccines: post-licensure safety evaluation. Clin Infect Dis 2001;33(Suppl 4):S327-33.
79. Kohl KS, Bonhoeffer J, Chen R, Heijbel H, Heininger U, Loupi E, Jefferson T, Duclos P. Safety reporting in clinical trials (letter). JAMA. 2001 Apr 25;285(16):2076-7.
80. Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M and VAERS Working Group. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics 2001 Jun;107(6):E97.
81. Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, Gorse GJ, Weniger BG, Newman BK, Yu O, and the Vaccine Safety Datalink Study Group. Safety and immunogenicity of varying doses of trivalent inactivated influenza vaccine administered by jet injector. Vaccine 2001;19:4703-9.
82. Davis RL, Rebolledo V, Christakis D, Immanuel V, Benson P, Barlow WE, Thmopson RS, Lewis N, Black SB, Shinefield HR, Mullooly JP, Ward JI, Vadheim CM, Marcy SM, Destefano F, Glasser JW, Rhodes PH, Chen RT. Risk of Seizures After Whole-Cell Pertussis or Measles Vaccination. New Engl J Med 2001;345:656-61.
83. Martin M, Weld L, Tsai T, Mootrey G, Chen R, Niu M, the GeoSentinel YF Working Group, Cetron M. Advanced Age as a Risk Factor for Adverse Events Temporally Associated with Yellow Fever Vaccination. Emerg Infect Dis 2001;7(6):945-51.
84. Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen R and VAERS Team. Enhancing the Vaccine Adverse Event Reporting System: a Capture-Recapture Analysis of Intussusception after Rotavirus Vaccination. Am J Epidemiol 2001; 154:1006–12..
85. Lewis E, Shinefield HR, Woodruff BA, Black SB, Destefano F, Chen RT, Ensor R, and the Vaccine Safety Datalink Workgroup. Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J 2001;20:1051-6.
86. Mullooly JP, Pearson J, Drew L, Schuler R, Maher J, DeStefano F, Gargiullo P, Chen RT, and the Vaccine Safety Datalink (VSD) Working Group. Wheezing Lower Respiratory Disease and Vaccination of Full-Term Infants. Pharmacoepidemiology and Drug Safety 2002; 11(1):21-30.
87. DeStefano F, Mullooly J, Okoro K, Chen RT, Vadheim C, Marcy M, Ward J, Black S, Shinefield H, Davis R, Bohlke K. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001; 108(6).URL: http://www.pediatrics.org/cgi/ content/full/108/6/e112.
88. DeStefano F and the Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiology and Drug Safety 2001; 10:1-4.
89. Lathrop S, Ball R, Haber P, Mootrey G, Braun M, Shadomy S, Chen R, Hayes E, and the VAERS Working Group. Adverse Event Reports Following Vaccination for Lyme Disease: December 1998-July 2000; Vaccine 2002;20:1603-8.
90. Ekwume D, Weniger B, Chen RT. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull WHO 2002 Dec;80:859-70.
91. DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco BF, Mullooly JP, Jackson LA, Davis RL, Black SB, Shinefield HR, Marcy SM, Ward JI, Chen RT. Childhood Vaccinations and Risk of Asthma. Ped Infect Dis J 2002;21:498-504.
92. Black S, Lewis E, Shinefield H, Fireman B, Ray P, DeStefano F, Chen R. Lack of association between receipt of conjugate Haemophilus influenzae type b vaccine (HBOC) in infancy and risk of type 1 (juvenile onset) diabetes: long term follow up of the HBOC efficacy trial cohort. Pediatr Infect Dis J 2002;21:568-9.
93. Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW, and the Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 2002;156:634–640
94. Lloyd JC, Haber P,Mootrey GT, Braun MM, Chen RT, and VAERS Working Group Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: Data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. Vaccine 2003; 21:25-26.
95. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, Jacobson RM, Gargiullo PM, and the VAERS team. Prevalence of anti-gelatin IgE antibodies in persons with anaphylaxis following measles-mumps-rubella vaccine in the U.S. Pediatrics 2002 Dec;110(6):e71.
96. Bonhoeffer J, KohlK, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E and The Brighton Collaboration. The Brighton Collaboration: Addressing the Need for Standardized Case Definitions of Adverse Events Following Immunization (AEFI). Vaccine 2002;21:298:302.
97. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, Mullooly JP, Thompson RS; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003 Oct;112(4):815-20.
98. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Chen RT, and the Vaccine Safety Datalink Research Group. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003 Apr;60:504-509.
99. DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev of Vaccines 2002 Dec;2(1):21-29.
100. Mell L, Davis RL, Mullooly JP, Black SB, Shinefield HR, Zangwill KM, Ward JI, Marcy SM, Chen RT. Polio Extra-Immunization in Children Less Than Two Years Old Following Changes in Immunization Recommendations. Pediatrics 2003 Feb;111:296–301.
101. Verstraeten T, DeStefano F, Chen RT and Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines 2003 Feb;2(1):21-29
102. Verstraeten T, Jumaan A, Mullooly J, Seward J, Izurieta H, DeStefano F, Black S, Chen R, and the Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use and measles-mumps-rubella vaccination. Pediatrics 2003 Aug;112:e98 –e103. URL: http://www.pediatrics.org/cgi/content/full/112/2/e98.
103. Naleway AL, Belongia EA, Greenlee, RT, Kieke BA, Chen RT, Shay DK. Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination. Ann Int Med 2003 Jul;139(1):1-7.
104. Kohl K, Bonhoeffer J, Chen R, Duclos P, Heijbel H, Heininger U, Loupi E and The Brighton Collaboration. The Brighton Collaboration: Enhancing comparability of vaccine safety data. Pharmacoepidemiol and Drug Safety 2003 Jun;12(4):335-40.
105. Chen R. Evaluation of Vaccine Safety Post-9/11: Role of Cohort and Case-Control Studies. Vaccine 2004 May;22:2047-2053.
106. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW for for the Vaccine Safety Datalink. Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults. N Engl J Med 2003 May;348:1747-55.
107. Chen RT. Vaccine safety issues: introduction. Semin Pediatr Infect Dis. 2003 Jul;14(3):187.
108. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT, for the Vaccine Safety Datalink team. Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases. Pediatrics 2003 Nov; 112:1039-48.
109. Gust DA, Gangarosa P, Hibbs B, Wilkins C, Ford K, Stuart M, Brown-Bryant R, Wallach G, Chen RT. The National Immunization Information Hotline. J of Health Communication 2004 Jul-Aug; 9(4):371-379.
110. Gust DA, Gangarosa P, Hibbs B, Pollard R, Wallach G, Chen RT. National Immunization Information Hotline: Calls Concerning Adverse Events, 1998-2000. J Health Communications 2004 Sep-Oct;9(5):387-94.
111. Mullooly J, Drew L, DeStefano F, Maher J, Bohlke K, Immanuel V, Black S, Lewis E, Ray P, Vadheim C, Lugg M, Chen RT. Quality Assessments of HMO Diagnosis Databases Used to Monitor Childhood Vaccine Safety. Methods of Information in Medicine 2004;43(2):163-70.
112. Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet. 2003 Oct 25;362(9393):1345-6.
113. Haber P, Zanardi LR, Chen RT, Mootrey GT, Pless R, English R, and Niu M and the VAERS Working Group. A Review of Rotavirus Vaccine Reports to the Vaccine Adverse Event Reporting System: More than Intussusception Alone? Pediatrics 2004 Apr;113(4):e353-9.
114. Muetsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Inactivated intranasal influenza vaccine and the risk of Bell’s Palsy in Switzerland. New Engl J Med 2004 Feb; 350:896-903.
115. Zhou WG, Pool V, Destefano F, Iskander JK, Haber P, Chen RT, and The VAERS Working Group. Bell’s Palsy After Parenteral Inactivated Influenza Vaccines: Reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Pharmacoepidemiology and Drug Safety 2004 Aug; 13: 505–510; and Reply to Editorial. Pharmacoepidemiology and Drug Safety 2004 Aug; 13: 515–517
116. Eriksen EM, Perlman JA, Miller A, Marcy SM, Lee H, Vadheim C, Zangwill KM, Chen RT, DeStefano F, Lewis E, Black S, Shinefield H, Ward JI. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project. Pediatr Infect Dis J. 2004 Jul;23(7):656-62.
117. Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, Braun MM, Chen RT. Understanding vaccine safety: information from the Vaccine Adverse Event Reporting System (VAERS). PIDJ 2004 Apr:23:287-94.
118. Barwick R for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet. 2004 Sep 11;364(9438):936.
119. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, Jackson LA, Chen R. Safety of the Trivalent Inactivated Influenza Vaccine Among Children: A Population-Based Study. Arch Pediatr Adolesc Med. 2004 Nov;158(11):1031-1036).
120. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005 May;16(3):336-41.
121. Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatric Annales 2004 Sept:33:599-607.
122. Haber P, DeStefano F, Angulo F, Iskander J, Shadomy S, Weintraub E, Chen RT, and the VAERS Team. Reporting Trends of Guillain - Barré Syndrome (GBS) after Influenza Vaccine: Vaccine Adverse Event Reporting System (VAERS) 1990-2003. JAMA 2004 Nov; 292(20):2478-81.
123. Mell, LK, Ogren DS, Davis RL, Mullooly JP, Black SB, Shinefield HR, Zangwill KM, Ward JI, Marcy SM, Chen RT for the CDC Vaccine Safety Datalink Project. Compliance with National Immunization Guidelines in Children Younger than Two Years: 1996-1999. Pediatrics 2005 Feb;115(2):461-7.
124. Belongia EA, Naleway A, Kieke B, Qutaishat S, Casey C, Shay DK, Chen RT. Validation of a Screening Instrument to Identify Persons for Exclusion from Smallpox Vaccination. Clin Infect Dis 2005 Jan 25; 40(4):620-3.
125. Khromava AY, Barwick Eidex RS, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS, and Yellow Fever Vaccine Safety Working Group. Yellow Fever Vaccine: an Updated Assessment of Advanced Age as a Risk Factor for Serious Adverse Events. Vaccine 2005 May 9;23(25):3256-63.
126. Folb PI, Bernatowska E, Chen R, Clemens J, Dodoo AN, Ellenberg SS, Farrington CP, John TJ, Lambert PH, Macdonald NE, Miller E, Salisbury D, Schmitt HJ, Siegrist CA, Wimalaratne O. A global perspective on vaccine safety and public health: the global advisory committee on vaccine safety. Am J Public Health. 2004 Nov;94(11):1926-31.
127. Thompson WW, Destefano F, Chen R. Letter to the editor. Vaccine. 2004 Dec 2;23(3):281-2.
128. Dayan GH, Iskander J, Glasser J, English-Bullard R, Fullerton KE, Chen R. Tracking vaccine lot lifecycles using reports to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and Drug Safety 2005 Oct;14(10):671-6.
129. Kohl K, Bonhoeffer J, Braun MM, Chen R, Duclos P, Heijbel H, Heininger U, Loupi E, Marcy SM, and The Brighton Collaboration. The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization. Advances in Patient Safety: From Research to Implementation. AHRQ Publication Nos. 0500212. February 2005;2: 87:101.. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/qual/advances/>
130. Chu SY, Chen RT. Vaccine safety monitoring in the United States. Vacunas 2004; 6 (Suppl): 1-4.]
131. Baggs J, Chen RT, Damon IK, Rotz L, Allen C, Fullerton KE, Casey C, Nordenberg D, Mootrey G. Safety Profile of Smallpox Vaccine: Insights from the Pre-Pre-Event Smallpox Vaccination Program. CID Apr 15;40(8):1133-40. Epub 2005 Mar 16.
132. DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study (Letter). Neurology. 2005 Apr 12;64(7):1317.
133. Muralles AA, Ray P, Black S, Shinefield H, Casey CG, Campbell S, Chen RT. Active telephone surveillance to evaluate adverse events among civilian smallpox vaccine recipients. Vaccine. 2006 Jan 23;24(4):476-84. Epub 2005 Aug 30.
134. Ray P, Hayward J, Michelson D, Lewis E, Schwalbe J, Black S, Shinefield H, Marcy M, Huff K, Ward J, Mullooly J, Chen R, Davis R; Vaccine Safety Datalink Group. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J. 2006 Sep;25(9):768-73.
135. Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, Jackson L, Mullooly JP, Zangwill KM, Marcy SM, Black SB, Lewis EM, Shinefield HR, Belongia E, Nordin J, Chen RT, Shay DK, Davis RL, DeStefano F; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006 Oct 25;296(16):1990-7.
136. Kohl KS, Gidudu J, Bonhoeffer J, Braun M, Buettcher M, Chen RT, Drammeh B, Duclos P, Heijbel H, Heininger U, Hummelman E, Jefferson T, Keller-Stanislawski B, Loupi E, Marcy SM.The Development of Standardized Case Definitions and Guidelines for Adverse Events Following Immunization. Vaccine 2007 Aug 1;25(31):5671-4. Epub 2007 Mar 12.
137. McMahon AW, Eidex RB, Marfin AA, Russell M, Sejvar JJ, Markoff L, Hayes EB, Chen RT, Ball R, Braun MM, Cetron M and the Yellow Fever Working Group\*. Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. Vaccine 2007 Feb 26;25(10):1727-34. Epub 2006 Nov 27.
138. Jackson ML, Nelson JC, Chen RT,. Davis RL, Jackson LA, for the Vaccine Safety Datalink investigators Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiology and Drug Safety 2007:16:1-7.
139. DeStefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis (letter). Pharmacoepidemiology and Drug Safety. 2007; 16: 705-707.
140. Fischer M, Casey C, and Chen RT. Promise of new Japanese encephalitis vaccines (commentary). Lancet 2007; 370 (9602): 1806-1808.
141. Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK, and The VAERS team. Live attenuated measles and mumps viral strain containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003. Vaccine 2008 Feb 26;26(9):1166-1172. Epub 2008 Jan 22. .
142. Chapman LE, Iskander JK, Chen RT for CDC with the Smallpox Vaccine Safety Working Group – Neff J, Birkhead G, Poland G, Gray GC, Siegel J, Sepkowitz K, Robertson RM, Yancy C, Guerra FA, Gardner P, Modlin JF, Mauer T, Berger T, Flanders WD, Shope R. The United States Smallpox Vaccine Safety Sentinel Review Process for Signal Clarification – 2003-2004. Clinical Infect Dis 2008 Mar 15;46 Suppl 3:S271-93.
143. France EK, Glanz, J; Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Lieu T, Chen R, Davis R, for the Vaccine Safety Datalink Team. Risk of Immune-Thrombocytopenic Purpura following Measles-Mumps-Rubella Immunization in Children. Pediatrics 2008 Mar;121(3):e687-92.
144. Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, Corcoran AT, Iskander JK, Schonberger LB, Chen RT. Anti-Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine-Associated Guillain-Barré Syndrome. J Infect Dis. 2008 Jun 3. [Epub ahead of print].
145. Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher M, Gold M, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, Kohl K, Marcy SM, Nalin D, Pless R, Sanabria-Rojas H, Sleeman K, Wise R; The Brighton Collaboration Methods Working Group.Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine. 2009 Apr 6;27(16):2289-97. Epub 2008 Dec 4.
146. Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher M, Gold M, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, Kohl K, Marcy SM, Nalin D, Pless R, Sanabria-Rojas H, Sleeman K, Wise R; The Brighton Collaboration Methods Working Group.Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine. 2009 Apr 6;27(16):2282-8. Epub 2008 Dec 3.

1. Marum L, Bennett E, Hightower A, Chen R, Kaiser R, Okello D, Mermin J, Sharif SK. The role of health care in the spread of HIV/AIDS in Africa: evidence from Kenya. Int J STD AIDS. 2009 Jan;20(1):69-70. [Letter]
2. Chen RT, Clark TA, Halperin SA. The yin and yang of paracetamol and paediatric immunisations. Lancet. 2009 Oct 17;374(9698):1305-6. [Commentary]
3. Gust DA, Wiegand RE, Para M, Chen RT, Bartholow BN. HIV Testing Outside of the Study Among Men Who Have Sex With Men Participating in an HIV Vaccine Efficacy Trial. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):294-8.
4. Gust DA, Wiegand RE, Kretsinger K, Sansom S, Kilmarx PH, Bartholow BN, Chen RT. [Circumcision status and HIV infection among MSM: reanalysis of a Phase III HIV vaccine clinical trial.](http://www.ncbi.nlm.nih.gov/pubmed/20168206) AIDS. 2010 May 15;24(8):1135-43.
5. Thompson B, Moro PL, Hancy K, Ortega-Sanchez I, Chen R, Santos-Preciado JI, Franco-Paredes C, Weniger B. Needlestick injury in Mexico City sanitation workers. Rev Panam Salud Publica. 2010 Jun;27(6):467-8. [Letter]
6. Gust DA, Kretsinger K, Gaul ZJ, Hefflefinger JD, Begley EB. Chen RT, Kilmarx PH. Adult male circumcision as an HIV prevention intervention in the U.S.: Influence of health care providers and potential for risk compensation. Am J Prev Med 2011;52:270–273.
7. Gust DA, Kretsinger K, Gaul Z, Pals S, Heffelfinger JD, Begley E, Chen RT,Kilmarx PH. Acceptability of Newborn Circumcision to Prevent HIV Infection in the United States. Sex Transm Dis. 2011 Jan 6. [Epub ahead of print] PubMed PMID:21217414.
8. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging Vaccine Informatics. Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 218590, 26 pages, 2010. doi:10.1155/2010/218590
9. DeStefano F, Vellozzi C, Schonberger LB, Chen RT. Adjuvanted pandemic influenza A (H1N1) 2009 vaccines and Guillain Barré syndrome (commentary). BMJ 2011; 343:d4159
10. Ray P, Black S, Shinefield H, Dillond A, Carpenter D, Lewis E, Ross P, Chen RT, Klein NP, Baxter R, and VSD Team. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine 2011 Sep 2;29(38):6592-6597. Epub 2011 Jul 16.
11. Hankins CA, Glasser JW, Chen RT. Modeling the impact of RV144-like vaccines on HIV transmission (commentary). Vaccine 2011 Aug 18;29(36):6069-71. Epub 2011 Jul 14. PubMed

PMID: 21762753.

1. Chen RT, Hu DJ, Dunne E, Shaw M, Mullins J, Rerks-Ngarm S. Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines. Vaccine 2011 Aug 18;29(36):6072-8. Epub 2011 Jul 13. PubMed PMID: 21745523.
2. Oloo I, Gust D, Shinde S, Mc Lellan-Lemal E, Pals S, Chege W, Gumbe A, Thomas T, Mills LA, Chen RT. Effect of Computerized Interview Voice Gender on Responses to Sensitive Sexual Behaviour Questions: use of Audio Computer-Assisted Self Interview (ACASI) in Kisumu, Kenya. Field Methods 2012 doi: 10.1177/1525822X11432087.
3. Carbery B, Zhu J, Gust DA, Chen RT, Kretsinger K, Kilmarx PH. Need for physician education on the benefits and risks of male circumcision in the United States. AIDS Education and Prevention 2012; 24(4):377-87.
4. Chege W, Pals SL, McLellan-Lemal E, Shinde S, Nyambura M, Otieno FO, Gust DA, Chen RT, Thomas TK. Baseline Findings of an HIV Incidence Cohort Study to Prepare for Future HIV Prevention Clinical Trials in Kisumu, Kenya. Journal of Infection in Developing Countries 2012 (in press).

Member of Team/Working Groups:

1. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000 Sep 13;284(10):1271-9.
2. DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.Pediatrics. 2000 Oct;106(4):E52.
3. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001 Feb;20(2):219-23.
4. Ball R, Braun MM, Mootrey GT; Vaccine Adverse Event Reporting System Working Group. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2001 May 1;32(9):1273-80. Epub 2001 Apr 3.
5. Silvers LE, Ellenberg SS, Wise RP, Varricchio FE, Mootrey GT, Salive ME. The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997. Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):279-85.
6. DeStefano F, Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):403-6.
7. Silvers LE, Varricchio FE, Ellenberg SS, Krueger CL, Wise RP, Salive ME. Pediatric deaths reported after vaccination: the utility of information obtained from parents. Am J Prev Med. 2002 Apr;22(3):170-6.
8. Ball R, Halsey N, Braun MM, Moulton LH, Gale AD, Rammohan K, Wiznitzer M, Johnson R, Salive ME; VAERS Working Group. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System.J Clin Epidemiol. 2002 Aug;55(8):819-24.
9. Woo EJ, Burwen DR, Gatumu SN, Ball R; Vaccine Adverse Event Reporting System Working Group. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2003 Aug 1;37(3):351-8. Epub 2003 Jul 22.
10. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J; V.A.E.R.S. Team. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006 Feb 6;24(6):703-7. Epub 2005 Aug 9.
11. Iskander J, Pool V, Zhou W, English-Bullard R; The VAERS Team. Data mining in the US using the Vaccine Adverse Event Reporting System. Drug Saf. 2006;29(5):375-84.
12. Varricchio F, Reed J; VAERS Working Group. Follow-up study of medication errors reported to the vaccine adverse event reporting system (VAERS). South Med J. 2006 May;99(5):486-9.
13. Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW; Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events.Am J Epidemiol. 2002 Oct 1;156(7):634-40.
14. González IM, Averhoff FM, Massoudi MS, Yusuf H, DeStefano F, Kramarz P, Maher JE, Mullooly JP, Chun C, Davis RL, Black SB, Shinefield HR; Vaccine Safety Datalink Team. Hepatitis B vaccination among adolescents in 3 large health maintenance organizations. Pediatrics. 2002 Nov;110(5):929-34.
15. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003 May 1;348(18):1747-55.
16. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, Mullooly JP, Thompson RS; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003 Oct;112(4):815-20.
17. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS; Vaccine Safety Datalink Team. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol. 2004 Mar;113(3):536-42.
18. Spector L, Groves F, DeStefano F, Liff J, Klein M, Mullooly J, Black S, Shinefield H, Ward J, Marcy M; Vaccine Safety Datalink Project. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia. Eur J Cancer. 2004 Mar;40(4):579-84.
19. Hazlehurst B, Mullooly J, Naleway A, Crane B. Detecting possible vaccination reactions in clinical notes. AMIA Annu Symp Proc. 2005:306-10.
20. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, Kleinman K, Mullooly JP, France EK. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006 Aug;59(8):808-18. Epub 2006 Mar 15.
21. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, Black S, Shay DK; Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007 Jan 15;25(5):846-55. Epub 2006 Sep 25.
22. Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, DeStefano F. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics. 2006 Nov;118(5):2032-7.
23. Lin ND, Kleinman K, Chan KA, Yu XJ, France EK, Wei F, Mullooly JP, Black S, Shay DK, Kolczak M, Lieu TA; Vaccine Safety Datalink Team.Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose. BMC Pediatr. 2006 Nov 13;6:31.
24. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F; Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007 Sep 27;357(13):1281-92.
25. Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R; for the Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007 Oct;45(10 Supl 2):S89-95.
26. Yu O, Bohlke K, Hanson CA, et al.. Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. Pharmacoepidemiology and Drug Safety. 2007; 16: 736-745.
27. Hinrichsen VL, Kruskal B, O’Brien MA, Lieu TA, Platt R, and Vaccine Safety Datalink Team. Using Electronic Medical Records to Enhance Detection and Reporting of Vaccine Adverse Events. J. Am. Med. Inform. Assoc. 2007; 14: 731-735. First published online as doi:10.1197/jamia.M2232.
28. Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ; Vaccine Safety Datalink. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pediatrics. 2008 Mar;121(3):463-9.
29. Chang MH, Lindegren ML, Butler MA, .. for the CDC/NCI NHANES III Genomics Working Group. Prevalence in the United States of Variants in Genes of Public Health Importance: Results from the Third National Health and Nutrition Examination Survey (NHANES III), 1991-1994. Am J Epidemiol. 2008 Oct 20. [Epub ahead of print].
30. Baxter R, Marchant C, Edwards K, Hrncir D, Jones J, Klein N, LaRussa P, Slade B, Vellozzi C, Wood R. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008 Sep;122(3):e771-7
31. Batra JS, Eriksen EM, Zangwill KM, Lee M, Marcy SM, Ward JI; Vaccine Safety Datalink. Evaluation of vaccine coverage for low birth weight infants during the first year of life in a large managed care population. Pediatrics. 2009 Mar;123(3):951-8.
32. Jackson LA, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009 Mar 25;9:37.
33. The Science Board of the Brighton Collaboration. Methodologic reporting requirements for clinical trials. Vaccine. 2011 Sep 16. [Epub ahead of print] PubMed PMID: 21930177.
34. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. for the HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. Epub 2011 Jul 18. PubMed PMID: 21767103

Books and Book Chapters:

1. Chen RT. Corynebacterial infections. Chapter 272 in Kelley WN, ed. Textbook of internal medicine. Philadelphia: J B Lippincott, 2nd edition, 1992;1377-1380.
2. Chen RT. Diphtheria. In Encyclopedia of Science and Technology. New York: McGraw\_Hill, 7th edition, 1992:313-4.
3. Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology, 2nd edition. Sussex: John Wiley & Sons, 1994:581-94.
4. Terracciano G, Chen R, Lloyd J. Surveillance for adverse events following vaccination. Ch. 17 In: Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention: Atlanta, GA, 1996.

1. Chen RT, Hardy IRB. Corynebacterial infections. Chapter 278 in Kelley WN, ed. Textbook of internal medicine. Philadelphia: J B Lippincott, 3rd edition, 1997;1627-9.
2. Chen RT. Diphtheria. In Encyclopedia of Science and Technology. New York: McGraw\_Hill, 8th edition, 1997:338-9.
3. Barnett ED, Chen RT, Rey M. Vaccine preventable diseases: the commercially available vaccines. In: Dupont HL, Steffen R, eds. Textbook of Travel Medicine and Health. Montreal: Decker 1997:154-168.
4. Cordero JF, Chen R. Vigilancia epidemiologica de evento adversos despué de la vacunacion. In: Marti MC, Llop FAM, eds. 1997 Vacunas. Barcelona: Prous Science; 1997:197-207.
5. Chen RT. Safety of Vaccines. Ch. 49 In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd edition. Philadelphia: WB Saunders, 1999:1144-63.
6. Barnett E, Chen RT, Rey M. Vaccines for International Travel. Ch. 44 In: Plotkin SA, Orenstein WA. Vaccines, 3rd edition. Philadelphia: WB Saunders 1999:1089-1106.
7. Terracciano GJ, Chen R. Vaccine safety and adverse events: key issues for health care workers. In: Poland GA, Schaffner W, Pugliese G, eds. Immunizing healthcare workers: a practical approach. Thorofare, NJ: Slack Inc 2000: 37-60.
8. Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology, 3rd edition. Sussex: John Wiley & Sons, 2000: 707-732.
9. Chen RT, Vitek C. Corynebacterial infections. In Kelley WN, ed. Textbook of internal medicine, 4th edition. Philadelphia: J B Lippincott, 2000:1984-6.
10. Barnett ED, Rey M, Chen RT. Vaccine preventable diseases: the commercially available vaccines. In: Dupont HL, Steffen R, eds. Textbook of Travel Medicine and Health, 2nd edition. Montreal: Decker 2000:232-51.
11. Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and Controversies in Immunization Safety. In: Peter G, Gardner P (eds.). Vaccine recommendations: challenges and controversies. Infect Dis Clinics of North America 2001;15:21-39.
12. Chen RT, Orenstein WA. Evaluation of Immunization Programs. In: Thomas JC, Weber DJ, eds. Epidemiologic Methods for Infectious Diseases. Oxford: Oxford University Press 2001:344-72.
13. Chen RT, Vitek C. Diphtheria. In Encyclopedia of Science and Technology. New York: McGraw\_Hill, 9th edition. 2002.
14. Chen RT, Davis R, Sheedy KM. Safety of Immunizations. Ch. 61 In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edition. Philadelphia: WB Saunders 2003:1557-81.
15. Chen RT, ed. Vaccine Safety Issues. Semin Pediatr Infect Dis. 2003 Jul;14(3).
16. Chen RT, Davis RL, Rhodes PH. Special methodological issues in pharmacoepidemiology studies of vaccine safety. Ch. 32 In: Strom BL, ed. Pharmacoepidemiology, 4rd edition. Sussex: John Wiley & Sons 2005:455-86.
17. Lee D, Majumdar SR, Lipton HL, Soumerai SB, Hennessy S, Davis RL, Chen RT, Bright RA, Mitchell AA, Graham DJ, Bates DW, and Strom BL. Special Applications of Pharmacoepidemiology. Ch. 27 in: Textbook of Pharmacoepidemiology In Strom BL & Kimmel SE, eds. Sussex: John Wiley & Sons, Ltd.2006:399-445.
18. Iskander JK, Chen RT. Vaccine preventable diseases PART 2: Public health surveillance for vaccine adverse events. Ch. 18 In: M'ikanatha NM, Lynfield R, Van Beneden CA, de Valk H, eds. Infectious Disease Surveillance, 1st edition. Oxford: Wiley-Blackwell 2007:241-53.
19. Sabin ME, Murphy TV, Chen RT. Rotavirus vaccines. Ch. 31 in: Hartzema AG, Tilson HH, Chan KA, eds. Pharmacoepidemiology and Therapeutic Risk Management, 1st edition. Cincinnati: Harvey Whitney Books 2008: 745-9.
20. Chen RT, Glanz, J, Vellozzi C. Special methodological issues in pharmacoepidemiology studies of vaccine safety. Ch. 26 In: Strom BL, ed. Pharmacoepidemiology, 5th edition. Sussex: John Wiley & Sons 2012:423-68.
21. Iskander JK, Chen RT. Vaccine safety monitoring. In: Sheikh NA, Davies DH, Schmidt C, Morrow, WJW, eds. Vaccinology –Principals and Practice, 1st edition. Oxford: Wiley-Blackwell (in press).

CDC Publications:

1. CDC. Pertussis \_ United States, 1982 and 1983. MMWR 1984;33:573\_575.
2. CDC. Pertussis \_ Washington, 1984. MMWR 1985;34:390\_394, 399\_400.
3. CDC. Vaccine Adverse Event Reporting System (VAERS): A new post-marketing surveillance system for all vaccines in the U.S. MMWR 1990; 730-733.
4. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR1993:42(RR-5).
5. CDC. Update: Vaccine Side Effects, Adverse Reactions, Contraindications, and Precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996:45(No RR-12).
6. CDC. Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-5).
7. CDC. Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2002 51(RR-17).
8. CDC. Adverse Events Associated with 17D-Derived Yellow Fever Vaccination —United States, 2001–2002. MMWR 2002;51: 989-993.
9. CDC. Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS) --- United States, 1991—2001. MMWR 2003; 52: SS1.
10. CDC. Cardiac Deaths After a Mass Smallpox Vaccination Campaign --- New York City, 1947. MMWR 2003; 52: 933-936
11. Iskander JK, Miller ER, Pless RP, Chen RT. Vaccine safety post-marketing surveillance: the Vaccine Adverse Event Reporting System. Continuing education activity number SS3092.
12. CDC. Suspension of Rotavirus Vaccine After Reports of Intussusception – United States, 1999. MMWR 2004;53:786-9.
13. Book review: Koff WC, Kahn P, and Gust ID, eds. AIDS Vaccine Development: Challenges and Opportunities. Emerging Infectious Diseases 2007; 13(11): 1802. [www.cdc.gov/eid](http://www.cdc.gov/eid)
14. CDC. Trends in in-hospital newborn male circumcision--United States, 1999-2010. MMWR 2011 60:1167-8. .

**Abstracts (Since 2000):**

1. Jackson LA, Chen RT, Austin G, Stout R, Gorse GJ, Weniger B, Yu O, Destefano F and the VSD Team. Safety, tolerability, and immunogenicity of varying doses of influenza vaccine administered by jet injector vs. needle and syringe. 3rd Annual Conference on Vaccine Research, Washington, DC Apr. 30-May 2, 2000.
2. Verstraeten TM, Baughman AL, Haber P, Chen RT. Enhancing the Vaccine Adverse Event Reporting System (VAERS) To Assess Risk: A Capture\_Recapture Analysis of Intussusception after Rotavirus Vaccination. 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
3. DeStefano F, Jackson LA, Okoro CA, Chen RT. Hepatitis B vaccination and demyelinating diseases – an interim analysis from the Vaccine Safety Datalink. 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
4. Pool V, Barker L, Chen RT. Evaluation of different data mining approaches for signal detection in the Vaccine Adverse Event Reporting System (VAERS). 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
5. Haber P, Mootrey G, Verstraeten TM, Pless R, Zanardi L, Chen RT. Rotavirus vaccine reports to the Vaccine Adverse Event Reporting System (VAERS) – assessing safety profiles of non-intussusception reports (poster). 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
6. Mullooly JP, Pearson J, Drew L, Schuler R, Garguillo P, Destefano F, Chen R. Risk of wheezing lower respiratory disease in infants after vaccination. 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
7. Goldman GS, Glasser JW, Maupin TJ, Peterson CL, Mascola L, Chen RT, Seward JF. The impact of vaccination on varicella incidence, conditional on school attendance and temperature, in Antelope Valley, CA. 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
8. Haber P, Mootrey GJ, Pless R, Chen RT. Vaccine Adverse Event Reporting System (VAERS), U.S. 1991-1999, a 9 year experience (poster) 16th International Conference on Pharmacoepidemiology, Barcelona, August 19-23, 2000.
9. DeStefano F, Okoro CA, Mullooly JP, Chen RT. Childhood Vaccinations and Type 1 Diabetes. 17th International Conference on Pharmacoepidemiology, Toronto, August 23-26, 2001.
10. Kohl KS, Hur Y, Rhodes P, Davis R, Chen R. Risk of Seizures Following Acellular Pertussis Vaccine - Results from a Large Linked Safety Database. 17th International Conference on Pharmacoepidemiology, Toronto, August 23-26, 2001.
11. Verstraeten T, Mullooly JP, Izurieta H, Jumaan A, Seward J, DeStefano F, Chen RT. Varicella Vaccine Failure in Children with Asthma. 17th International Conference on Pharmacoepidemiology, Toronto, August 23-26, 2001.
12. Pool V, Pless RP, Chen RT. Reporting Trends of Hypersensitivity Reactions in VAERS Following Live Virus Vaccines Containing Gelatin (poster). 17th International Conference on Pharmacoepidemiology, Toronto, August 23-26, 2001.
13. Kohl KS, Bonhoeffer J, Chen R, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: An International Collaborative Effort To Enhance Comparability of Vaccine Safety Data (poster). 17th International Conference on Pharmacoepidemiology, Toronto, August 23-26, 2001.
14. Chen RT. Ensuring public confidence in vaccine safety: some lessons from Enron and other public fiascos. 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
15. Zhou W, Pool V, Pless, RP, Chen RT. Descriptive case-series analysis of Bell’s Palsy cases in the Vaccine Adverse Event Reporting System (VAERS). 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
16. Pool V, Pless, RP, Chen RT. Severe local reactions following booster doses of DTaP vaccines in the U.S.: a signal from the Vaccine Adverse Event Reporting System (VAERS). 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
17. Casey C, Mootry G, Pool V, Pless RP, Hur Y, Chen RT. Investigation of a cluster of cellulitis following smallpox vaccination. 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
18. Dayan G, Iskander JK, English-Bullard R, Glasser J, Chen RT. Tracking the lifecycle of vaccines and vaccine lots via the Vaccine Adverse Event Reporting System (VAERS) (poster). 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
19. Rashidee AH, Chen R, Lugg MM, Black S. Integrating vaccine safety initiatives in immunization registry/systems (poster). 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
20. Iskander JK, Dayan G, English-Bullard R, Fullerton K, Glasser J, Chen RT, Wise RP, Bechtel C. Use of VAERS reports to estimate percentage of remaining thimerosal-containing vaccine (poster). 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
21. Kohl KS, Bonhoeffer J, Chen R, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: Enhancing Comparability of Vaccine Safety Data. 18th International Conference on Pharmacoepidemiology, Edinburgh, August 18-21, 2002.
22. Pool V, Chen RT. Association Rule Discovery as a Signal Generation Tool for the Vaccine Adverse Event Reporting System. 19th International Conference on Pharmacoepidemiology, Philadelphia, August 22-24, 2003.
23. Khromava A, Pool V, Chen R. Oculo-Respiratory Syndrome Following Influenza Vaccine –United States, 1990-2002: New or Previously Unrecognized? 19th International Conference on Pharmacoepidemiology, Philadelphia, August 22-24, 2003.
24. Offit P, Strom BL, Everett W, Riddle R, Iskander J, Chen R. Smallpox Vaccination: From Policy to Implementation. 19th International Conference on Pharmacoepidemiology, Philadelphia, August 22-24, 2003.
25. Haber P, Rashidee A, Zhou W, English-Bullard R, the VAERS team. Web-Based Reporting: 10 Months Experience in the Vaccine Adverse Event Reporting System (VAERS) (poster). 19th International Conference on Pharmacoepidemiology, Philadelphia, August 22-24, 2003.
26. Rhodes PR, DeStefano F, Chen RT and the MCO RRV-TV Safety Cohort Study Group. Long-term risk of intussusception following Rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV). 43rd ICAAC, Chicago, Illinois, September 17, 2003.
27. Barwick RS, Marfin AA, Chen R, Simone P, Cetron MS and the Yellow Fever Vaccine Safety Working Group. Age-associated risk of yellow fever vaccine-associated viscerotropic disease and neurotropic disease. Program and Abstracts of the IVth European Conference on Travel Medicine, Rome, Italy, March 29-31, 2004.
28. Casey CG, Campbell S, Iskander J,DeStefano F, Dekker CL, Gold MS,Zanoni G,Vermeer-de Bondt PE, Engler RJM, Chen RT Clinical Assessment of Adverse Events Following Immunization (AEFIs): A Converging New International Paradigm? 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-25, 2004.
29. Frank DeStefano, Eric SWeintraub, Robert T Chen. Determining Risk of Multiple Sclerosis after Hepatitis B Vaccine: Time Since Vaccination and Source of Data. 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-25, 2004.
30. Khromava A, Rhodes P, Shay D, Swerdlow D, Destefano F, Chen R.Do Live Viral Vaccinations (Other Than Smallpox) Increase the Risk of Cardiomyopathy in Adults? 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-25, 2004.
31. Calugar A, Pool V, Reef S, Zhou W, Chen RT. Inadvertent Rubella Vaccination during Pregnancy: Review of Reports to the U.S. Vaccine Adverse Event Reporting System (VAERS), 1991–2003. 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-25, 2004.
32. Zhou W, Pool V, Chen RT. Reports of Brachial Neuritis in the Vaccine Adverse Event Reporting System (VAERS), United States, 1991–2003. 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-25, 2004.
33. J. Iskander, V. Pool, R. English-Bullard, R.T. Chen and the CDC VAERS Team. Increasing complexity of vaccine safety surveillance databases: the case for “data mining”. International Society of Pharmacovigilance (ISoP), Dublin, Ireland, October 6-8, 2004.
34. Barwick Eidex R, Miller E, Russell MN, Teuwen D, Montah T, Hayes EB, Marfin A, Iskander J, Chen R, Cetron MS, Yellow Fever Vaccine Safety Working Group. Thymus disease as a potential risk factor for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Program and Abstracts of the 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, FL, November 7-11, 2004.
35. Chen RT, Post G, Millogo J, Van Roekel K, Catlin M, Clark K. Making Medical Injection Safer: A Major Step towards Enhancing Patient Safety in Developing Countries. 21th International Conference on Pharmacoepidemiology, Nashville, TN, August 21-24, 2005.
36. Miller ER, Iskander JK, Haber P, Gangarosa P, Pool V, Chen RT. Monitoring of Vaccine Safety Inquiries: A New Tool for Vaccine Safety Signal Generation 21th International Conference on Pharmacoepidemiology, Nashville, TN, August 21-24, 2005.
37. Pool V, James SP, Chen RT. ASSIGN: A Proactive Systematic Approach to Vaccine-Vigilance in the U.S. Vaccine Adverse Event Reporting System. 21th International Conference on Pharmacoepidemiology, Nashville, TN, August 21-24, 2005.
38. Rue AM, Lyn S, Iskander JK, Bloestein J, Gargiullo P, Shadomy S, Seward J, Chen RT. Investigation of Deaths and Serious Illnesses Following Influenza Vaccination in a Long-Term Care Facility. 21th International Conference on Pharmacoepidemiology, Nashville, TN, August 21-24, 2005.
39. Asatryan A, Pool V, Chen RT. Sensorineural Hearing Loss Following Measles-Mumps-Rubella Vaccination: Vaccine Adverse Event Reporting System, United States, 1991–2004. 21th International Conference on Pharmacoepidemiology, Nashville, TN, August 21-24, 2005.
40. Chen RT, Songa J, Mwangi J, Lore B, Khan F. Kenya’s “Top down approach” to improve rational injections. Global Injection Safety and Infection Control Meeting. 23-25 October 2006, Mexico City, Mexico
41. Colton JS, Chen R. Fabrication and analysis of plastic hypodermic needles. Global Injection Safety and Infection Control Meeting. 23-25 October 2006, Mexico City, Mexico
42. Chen R, Catlin M, Lasley J, Songa J, Millogo J, Ferris R, Post G. A model to budget for sharps waste management in resource-scarce settings. Global Injection Safety and Infection Control Meeting. 23-25 October 2006, Mexico City, Mexico
43. Chen RT. AIDS Vaccines Update: Making Sense of the Vaccine Development Process – Basic Research Literacy and Lessons Learned from Vaccine History. A Collaborative Symposium in advance of the AIDS Vaccine Conference 2008, Capetown, South Africa, Oct. 13, 2008.
44. Chen, RT; Excler JL; Laderoute M; Mahy B1; Hendry M; Via Cl; Compingbutra A; Gidudu J on behalf of the V3SWG. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG): Maximizing the Comparability and Value of Safety Data from HIV Vaccine Trials. AIDS Vaccine 2009, Paris, France, Oct. 19-22, 2009.
45. Gomez V, Palomeque FS, Feris J, Fernández J, Sánchez J, Moro PL, Mota1 CS, Sánchez V, Guzmán G, Bridges CB, Bresee JS, Friede M, Zehrung D, Chen RT, Weniger BG. Still-blinded Safety and Immunogenicity Data from a Trial of Reduced-dose, Intradermal, Influenza Vaccination by Needle-free Jet Injection. Thirteenth Annual Conference on Vaccine Research, April 26– 28, 2010, Bethesda, Maryland
46. El Bcheraoui C, Greenspan J, Kretsinger K, Chen R. Rates of selected neonatal male circumcision-associated severe adverse events in the United States, 2007-2009. XVIII AIDS Conference (AIDS 2010), Vienna, Austria, July 18-23, 2010.
47. Chen RT, Hankins C, Osmanov S, Esparza J, Michael NL, McCluskey M, Warren M. Preparing for the availability of a partially effective HIV vaccine. AIDS Vaccine 2011, Bangkok, Thailand, Sept. 12 – 15, 2011.
48. Long EF, Andersson KM, Chen RT, Glasser JW, Hankins CA, Harmon T, Owens DK. A model-based consensus on the impact of an RV144-like HIV vaccine in diverse epidemic settings".XIX AIDS Conference (AIDS 2012), Washington, D.C., July 22-27, 2012.

# Invited Presentations or Talks (Since 2000):

1. Vaccine Safety Monitoring: A New Imperative for Immunization Programs. Korean Conference on Emerging Infectious Diseases, Seoul, Korea, April, 2000.
2. Vaccine Safety Update. Association of State and Territorial Health Officials (ASTHO) Infectious Disease Policy Committee, Atlanta, GA, May 19, 2000.
3. Establishing Causality in Vaccine Safety Studies: Lines of Evidence. Pan American Health Organization (PAHO) Expanded Program in Immunizations (EPI) Technical Advisory Group (TAG) meeting. Iguasu Falls, Brazil, May 2000.
4. Update on Vaccine Safety Monitoring in the U.S.: Sustaining Mature Immunization Programs. World Vaccine Congress, Paris, France, September, 2000. Update on Vaccine Safety Monitoring in the U.S.: Sustaining Mature Immunization Programs. European Society of Pharmacovigilance, Verona, Italy, September, 2000.
5. Vaccine Safety. Vaccines are beneficial! What are the risks? Berzelius symposium on vaccines, Stockholm, Sweden. February, 2001.
6. Update on Vaccine Safety. 7th Conference of the International Society of Travel Medicine, Innsbruck, Austria, May 27-31, 2001.
7. Vaccine Triggers for Intussusception? and Measuring Vaccines: Benefits and Risks. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL. September 22-25, 2001.
8. Maintaining Public Confidence in Immunizations: Role of Vaccine Safety at CDC. AAP Chapter Advocacy Summit, Atlanta, Georgia. November 9-11, 2001.
9. La seguridad de las vacunaciones sistemáticas. First Congress of the Spanish Association of Vaccinology, Cadiz, Spain, 15-17 November, 2001
10. Issues in Vaccine Safety. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, December 16-19, 2001.
11. Vaccine Safety: A Cumulative Scientific Endeavor and Combination Vaccines: Meeting the New Opportunities and Challenges. 7th annual Massachusetts Immunization Action Partership, Worchester, MA, May 16, 2002.
12. Cohort and case-control studies in the evaluation of safety of vaccines. The First International Symposium on The Evaluation of The Safety of Human Vaccines, Rome, Italy 22-23 May 2002.
13. Epidemiologic assessment of serious adverse events. Fourth Advanced Vaccinology Course. Annecy, France. June 12, 2002.
14. World Vaccine Congress Montreal 2002
15. CDC Perspective. New York State Vaccine Safety Summit. Cooperstown, NY. November 9-11, 2002.
16. Prospects of Combined Vaccines with Special Reference to Immunogenicity and Safety. First Emirates Conference on Vaccination, Dubai, UAE, December 14 -16, 2002.
17. Immunization safety monitoring system in the US. Vaccination in Tomorrow’s Society: New Information Pathways. Veyrier du Lac, France, 26-28 February 2003.
18. Dealing with the consequences of litigation - increased regulation and lower take up of vaccination programmes. World Vaccine Congress Montreal 2003, Montreal Canada, 7-9 April 2003.
19. Immunization Safety: An Emerging Imperative. 30th annual Pediatrics by the Sea, GA chapter of American Academy of Pediatrics, Sea Island, GA, June 13, 2003.
20. Symposia on Vaccine Safety. Pediatric Infectious Disease Society Conference, San Diego CA, October 13 and 14, 2003.
21. Immunization Safety: An Emerging Imperative. American College of Clinical Pharmacy Annual Meeting, Atlanta, GA. November 3, 2003.
22. Vaccine Safety: An Emerging Imperative. Symposium of the Dutch Society for Infection Diseases, Utrecht, The Netherlands, February 19, 2004.
23. Vaccine Safety: in Epidemiology 232 (Pharmacoepidemiology), graduate course in the Department of Epidemiology, School of Public Health of the University of North Carolina at Chapel Hill. Instructor: Harry Guess MD PhD. November 1, 2004.
24. Vaccine Safety: in Immunology 610 (Vaccines & Immune Therapeutics), graduate course in the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA. Instructors: Paul Offit MD and David Weiner MD, November 17, 2004.
25. Vaccine Safety Monitoring: in Public Health Surveillance Systems, graduate course in the Rollins School of Public Helath, Emory University, Atlanta GA. Instructor: Vicki S Hertzberg PhD, December 13, 2004.
26. Inaugural Catherine Peckham lecture, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health London, UK, August 7, 2005.
27. SIGN: some insights from inception to implementation. Global Injection Safety and Infection Control Meeting. 14 -16 November 2005, Hanoi, Viet Nam.
28. Plastic Hypodermic Needles: An Affordable "Green" Solution to the Iatrogenic Disaster of Unsafe Injections. CDC Technology Forum, March23-24, 2006, Atlanta GA.
29. Case Studies of possible evaluations that would use a global vaccine safety data net: HIV vaccine. Global Vaccine Safety DataNet Meeting, Sept 11-13, 2007, Annecy France.
30. Enhancing vaccine safety assessment during vaccine development: some modest proposals. 2nd Global Congress on Vaccine. 7th – 9th December 2008, Boston, MA, USA
31. Science and Practice: Establishing the Evidence for Vaccines: the intriguing tale of Diphtheria: from von Behring to Moscow, Apr. 24, 2009, ECDC, Stockholm, Sweden.
32. What can be learned from vaccine adverse events surveillance for vaccine positive events? Current challenges and new methodological approaches to assess vaccine effectiveness and vaccination impact, Sept. 28-30 2009, Annecy, France.
33. Vaccine Safety Strategic Issues. Distributed Networks: Opportunities and Challenges.   
    International Society of Pharmacoepidemiology Mid-Year Symposium   
    April 12, 2010, Raleigh, NC.
34. HIV Vaccine: The Spring after a Long Winter? and A “Lifecycle” Approach to Vaccine Safety: Global Trends and Challenges. Sept. 24, 2010. 5th Asian Congress of Pediatric Infectious Diseases, Taipei, Taiwan.
35. Preparing for the Availability of a Partially Effective HIV Vaccine. Satellite symposium, AIDS Vaccine 2010, Sept. 28, 2010, Atlanta GA.
36. Brighton Collaboration Viral Vector Vaccines Safety Working Group. Global Collaborative Network for Vaccine Safety Studies. March 28-30, 2011, Veyrier-du-Lac, France.
37. Optimal safety assessment system for future vaccines against poverty-related diseases   
    (PRD:HIV, malaria, TB) in developing countries. Meeting on Post-licensure Evaluation of Vaccine Safety: Current Status and Future Directions. International Alliance for Biological Standardization, April 27-28, 2011, Barcelona, Spain.
38. Optimal safety assessment system for future vaccines against poverty-related diseases   
    (PRD:HIV, malaria, TB) in developing countries. 5th Vaccine and ISV Annual Global Congress, Oct. 4, 2011. Seattle, WA.